Although the number of afatinib cases was relatively low, it did not reach statistical significance.
← all excerpts
The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study.
1
—
—